Patents by Inventor C. Michael Philbrook
C. Michael Philbrook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11793749Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: GrantFiled: August 20, 2021Date of Patent: October 24, 2023Assignee: Genzyme CorporationInventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Publication number: 20220110861Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: ApplicationFiled: August 20, 2021Publication date: April 14, 2022Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Patent number: 11110055Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: GrantFiled: January 4, 2019Date of Patent: September 7, 2021Assignee: Genzyme CorporationInventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Publication number: 20200048222Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: ApplicationFiled: January 4, 2019Publication date: February 13, 2020Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos
-
Patent number: 10219998Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: GrantFiled: December 17, 2015Date of Patent: March 5, 2019Assignee: Genzyme CorporationInventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Publication number: 20180000728Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: ApplicationFiled: December 17, 2015Publication date: January 4, 2018Applicant: GENZYME CORPORATIONInventors: Harvey LIEBERMAN, Donglai YANG, C. Michael PHILBROOK, Michael SANTOS, Chris HO
-
Publication number: 20170281641Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-receptor kinase B (TrkB), tropomyosin-receptor kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).Type: ApplicationFiled: September 2, 2015Publication date: October 5, 2017Inventors: Kerry DONAHUE, C. Michael PHILBROOK, Dominick BLASIOLI, John L. KANE, Carl FLANNERY
-
Patent number: 7250177Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: GrantFiled: June 22, 2005Date of Patent: July 31, 2007Assignee: Genzyme CorporationInventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Patent number: 7074424Abstract: Hyaluronic acid and polyalkylene glycol (PAG) based materials have been found to exhibit a synergistic interaction, in which the viscosity of the mixture is more than twice as high as the viscosity expected from the viscosity of the individual components. The mixture otherwise has similar properties to those of its constituents, and in particular will crosslink to form covalently crosslinked gels if the PEG carries crosslinkable groups. The viscous formulation adheres well to tissue, and has applications as a tissue sealant and in tissue coating, prevention of adhesions, cell immobilization, regeneration of cartilage, bone and other tissue, as well as in controlled delivery of hyaluronic acid to sites in the body. Related materials exhibit similar effects.Type: GrantFiled: November 28, 2001Date of Patent: July 11, 2006Assignee: Genzyme CorporationInventors: Luis Z. Avila, Peter K. Jarrett, Hildegard M. Kramer, C. Michael Philbrook
-
Patent number: 7022343Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.Type: GrantFiled: December 27, 2001Date of Patent: April 4, 2006Assignee: Genzyme CorporationInventors: C. Michael Philbrook, James W. Burns, Kevin C. Skinner, Robert J. Miller
-
Patent number: 6923986Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: GrantFiled: August 27, 2003Date of Patent: August 2, 2005Assignee: Genzyme CorporationInventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Publication number: 20040072961Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: ApplicationFiled: August 27, 2003Publication date: April 15, 2004Applicant: Focal, IncInventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Patent number: 6639014Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: GrantFiled: April 2, 2002Date of Patent: October 28, 2003Assignee: Focal, Inc.Inventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Publication number: 20020187182Abstract: A porous, water-absorbing fleece is made from crosslinkable biocompatible and biodegradable macromers. A solution of the macromers is frozen and vacuum-dried through lyophilization. The “fleece” formed by lyophilization is then crosslinked, for example by heat and/or an initiator of crosslinking. The resulting crosslinked material is highly water absorbent, readily swelling to at least its size before lyophilization, but retains macroporosity as well as the microporosity of a gel. Porosity and strength of the fleece can be controlled by initial polymer concentration and extent of crosslinking. The fleece materials can be used in different embodiments for applications in medicine and tissue engineering.Type: ApplicationFiled: February 14, 2002Publication date: December 12, 2002Applicant: Genzyme CorporationInventors: Hildegard M. Kramer, Luis Z. Avila, C. Michael Philbrook, Peter K. Jarrett, Barbara A. Huibregtse, Liesbeth M.E. Brown, Kenneth A. Messier, Michael J. Bassett, Edward J. Doherty, John A. Traverse
-
Publication number: 20020150622Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.Type: ApplicationFiled: December 27, 2001Publication date: October 17, 2002Applicant: Genzyme CorporationInventors: C. Michael Philbrook, James W. Burns, Kevin C. Skinner, Robert J. Miller
-
Publication number: 20020151650Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: ApplicationFiled: April 2, 2002Publication date: October 17, 2002Applicant: Focal, Inc.Inventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Publication number: 20020127196Abstract: Hyaluronic acid and polyalkylene glycol (PAG) based materials have been found to exhibit a synergistic interaction, in which the viscosity of the mixture is more than twice as high as the viscosity expected from the viscosity of the individual components. The mixture otherwise has similar properties to those of its constituents, and in particular will crosslink to form covalently crosslinked gels if the PEG carries crosslinkable groups. The viscous formulation adheres well to tissue, and has applications as a tissue sealant and in tissue coating, prevention of adhesions, cell immobilization, regeneration of cartilage, bone and other tissue, as well as in controlled delivery of hyaluronic acid to sites in the body. Related materials exhibit similar effects.Type: ApplicationFiled: November 28, 2001Publication date: September 12, 2002Applicant: Focal, Inc.Inventors: Luis Z. Avila, Peter K. Jarrett, Hildegard M. Kramer, C. Michael Philbrook
-
Patent number: 6410645Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: GrantFiled: November 9, 2000Date of Patent: June 25, 2002Assignee: Focal, Inc.Inventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Patent number: 6201065Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: GrantFiled: July 26, 1996Date of Patent: March 13, 2001Assignee: Focal, Inc.Inventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Patent number: 6162241Abstract: A method of controlling hemostasis by applying a hemostatic agent in a tissue sealant composition. The tissue sealant is a biodegradable, biocompatible synthetic polymer that may not intrinsically possess strong hemostatic properties. Inclusion of a hemostatic material in the tissue sealant can control bleeding at the site and may also provide improved adherence of the sealant to tissue and provide shorter healing times.Type: GrantFiled: August 5, 1998Date of Patent: December 19, 2000Assignee: Focal, Inc.Inventors: Arthur J. Coury, Amarpreet S. Sawhney, Jeffrey A. Hubbell, C. Michael Philbrook